Paper Details

  1. Home
  2. Paper Details

Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial.

Author: ChiKim N, EiglBernhard J, FinchDaygen L, GleaveMartin E, IvanovNikita, KhalafDaniel J, KollmannsbergerChristian K, OjaConrad, SunderlandKatherine, VergidisJoanna, ZulfiqarMuhammad

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Abiraterone was associated with better patient-reported health-related quality of life (HRQoL) and depression symptoms compared to enzalutamide. The study found that differences in the total FACT-P scores were seen only in the elderly patient subgroup.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Abiraterone and enzalutamide are associated with side effects that may impair health-related quality of life (HRQoL). OBJECTIVE: To assess patient-reported HRQoL, depression symptoms, and cognitive function for abiraterone versus enzalutamide. DESIGN, SETTING, AND PARTICIPANTS: We rand...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.eururo.2018.12.015

データ提供：米国国立医学図書館（NLM）

Metastatic Prostate Cancer: Comparing Abiraterone and Enzalutamide

The fight against cancer, like a journey across a vast desert, is often fraught with challenges. This study explores the impact of two distinct treatments for metastatic castration-resistant prostate cancer: abiraterone and enzalutamide. The study aims to compare these treatments, focusing on their impact on health-related quality of life and cognitive function.

Abiraterone vs. Enzalutamide: Quality of Life and Cognitive Function

The study, like a compass guiding us through the complexities of cancer treatment, suggests that abiraterone may be associated with better health-related quality of life compared to enzalutamide. The study also found that the difference in total FACT-P scores was particularly pronounced in elderly patients. These findings underscore the importance of individualized care and considering the specific needs of each patient.

What Does This Mean for Prostate Cancer Patients?

This study provides valuable insights into the impact of different treatments on the quality of life of prostate cancer patients. It's important to discuss your specific concerns and goals with your doctor to determine the best treatment plan for you.

Dr.Camel's Conclusion

This study, like a beacon of hope in the desert of cancer research, reminds us that the pursuit of effective treatments must always include consideration for the patient's overall well-being. The study underscores the need for individualized care and emphasizes the importance of understanding the potential impact of treatment on quality of life.

Date :
  1. Date Completed 2020-07-23
  2. Date Revised 2021-12-04
Further Info :

Pubmed ID

30591354

DOI: Digital Object Identifier

10.1016/j.eururo.2018.12.015

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.